GFAPδ: A Promising Biomarker and Therapeutic Target in Glioblastoma

Area of Science:

• Neuroscience
• Molecular Biology
• Oncology

Background:

• Glial fibrillary acidic protein delta (GFAPδ) is an alternative splice variant primarily found in the brain's subventricular zone.
• GFAPδ expression is linked to neural stem cell markers and has been investigated in relation to brain tumor progression.

Purpose of the Study:

• To review the existing literature on GFAPδ in astrocytoma.
• To emphasize the role of GFAPδ as a potential biomarker for malignancy and invasiveness.
• To explore GFAPδ as a possible therapeutic target in glioblastoma.

Main Methods:

• Literature review of studies investigating GFAPδ expression in astrocytoma.
• Analysis of correlations between GFAPδ expression levels and glioma grade, malignancy, and invasiveness.
• Examination of the impact of GFAPδ/α ratio on gene expression and cellular behavior.

Main Results:

• GFAPδ is overexpressed in high-grade glioblastomas (CNS WHO grade 4) compared to lower-grade gliomas.
• A higher GFAPδ/α ratio is associated with more malignant and invasive glioma phenotypes.
• Altered GFAPδ/α ratios influence the expression of genes linked to high-grade malignancy.

Conclusions:

• The differential expression of GFAP isoforms (GFAPδ vs. GFAPα) is valuable for assessing astrocytoma malignancy.
• GFAPδ shows promise as a biomarker for predicting glioma behavior and aiding in classification.
• GFAPδ represents a potential therapeutic target for glioblastoma treatment.